Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
Pharmaceutical
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales28@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Atazanavir (ATV) - Once-Daily HIV Protease Inhibitor
Product Overview:
Azanavir is a new type of HIV-1 protease inhibitor developed by Bristol-Myers Squibb. Azanavir sulfate was released in the United States on June 20, 2003 and in Europe on March 2, 2004 under the trade name Reyataz.
Atazanavir (ATV) - Once-Daily HIV Protease Inhibitor Attributes
CAS:198904-31-3
MF:C7H15NO3
MW:161.2
EINECS:208-768-0
Specification: 99% min Atazanavir Powder
Sample:Atazanavir Powder Avaliable
Packaging:1kg/bag, 25kg/drum
Brand: Ausreson
Appearance:white powder
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Atazanavir (ATV) - Once-Daily HIV Protease Inhibitor Details
Atazanavir Powder Usage and Synthesis.
Azanavir is an inhibitor of azeptide HIV-1 protease. The product selectively inhibits the specific processing of viral Gag and GAG-pol polymers in HIV-1-infected cells, thereby blocking the formation of mature viruses. In vitro antiviral activity: The mean 50% inhibitory concentration (IC50) of azanavir against a large number of laboratory and clinical isolates of HIV-1 virus isolated from peripheral blood mononuclear cells, macrophages, CIM-SS cells, and MT2 cells without human serum was 2-5 nm.
Pharmacological action of Atazanavir.
Azanavir is a novel azopeptidase protease inhibitor (PI), whose activity in vitro is comparable to that of non-peptide PIs such as Nelfinavir. Azanavir is designed based on X-ray diffraction studies of enzym-azopeptidase complexes and has a C-2 symmetric chemical structure. It is a highly selective and efficient inhibitor of HIV-1 protease, which inhibits the production of viral structural proteins, reverse transcriptase, integrase and protease by blocking the cleavage of viral gap and GAP-POL precursor polymerase, so that HIV-1-infected cells release non-infectious immature viral particles. This product has stronger inhibitory activity against multiple strains of HIV-1 virus than other PIs, and the median effective concentration (EC50) in vitro medium is 2.6 ~ 5.3nmol/L, and the 90% effective concentration (EC90) is 9 ~ 15nmol/L.
In vitro study of Atazanavir.
Atazanavir has effective activity against wild-type viruses in vitro with EC50 and EC90 of 2-5 nM and 9-15 nM, respectively. Atazanavir can effectively induce endoplasmic reticulum stress response in glioma cells, and the levels of GRP78 and CHOP are increased, and caspase-4 is activated, leading to cell death.
Our Strengths.
Henrikang has the ability to manufacture capsules for any formulation. From sourcing each ingredient in the formulation to post-fill inspection, we can do it all at the best price and with the fastest delivery time.
We have the experience to help you formulate new products for your target customers or discuss with you the appropriate scale-up of production. As your partner, our job is to ensure the long-term success of capsule production.
Be sure to check out our products. There, you can see what we consider to be the best formulations, all of which have their own specialties. They may provide a variety of beneficial vitamins and nutrients.
Signs of a good capsule supplement include taste, color, shape, size, and more. We have carefully weighed these factors and compiled a catalog of some of the very best formulas we have for you today.


